- Home
- VEL vs TERN Comparison
VEL vs TERN Comparison
Compare VEL & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VEL
- TERN
- Stock Information
- Founded
- VEL 2004
- TERN 2017
- Country
- VEL United States
- TERN United States
- Employees
- VEL N/A
- TERN N/A
- Industry
- VEL Finance: Consumer Services
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- VEL Finance
- TERN Health Care
- Exchange
- VEL Nasdaq
- TERN Nasdaq
- Market Cap
- VEL 602.1M
- TERN 495.2M
- IPO Year
- VEL 2020
- TERN 2021
- Fundamental
- Price
- VEL $19.16
- TERN $6.93
- Analyst Decision
- VEL Buy
- TERN Buy
- Analyst Count
- VEL 5
- TERN 5
- Target Price
- VEL $21.20
- TERN $15.63
- AVG Volume (30 Days)
- VEL 99.6K
- TERN 1.1M
- Earning Date
- VEL 08-07-2025
- TERN 08-05-2025
- Dividend Yield
- VEL N/A
- TERN N/A
- EPS Growth
- VEL 26.95
- TERN N/A
- EPS
- VEL 2.22
- TERN N/A
- Revenue
- VEL $195,592,000.00
- TERN N/A
- Revenue This Year
- VEL N/A
- TERN N/A
- Revenue Next Year
- VEL $32.82
- TERN N/A
- P/E Ratio
- VEL $8.65
- TERN N/A
- Revenue Growth
- VEL 44.29
- TERN N/A
- 52 Week Low
- VEL $16.12
- TERN $1.87
- 52 Week High
- VEL $20.98
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- VEL 65.99
- TERN 64.82
- Support Level
- VEL $18.61
- TERN $6.23
- Resistance Level
- VEL $19.19
- TERN $7.16
- Average True Range (ATR)
- VEL 0.46
- TERN 0.48
- MACD
- VEL 0.18
- TERN -0.01
- Stochastic Oscillator
- VEL 96.66
- TERN 87.36
About VEL Velocity Financial Inc.
Velocity Financial Inc is a United States-based real estate finance company. The company originates and manages investor loans secured by residential rental and small commercial properties. The company earns revenue in the form of interest income. It operates in New York, California, Florida, New Jersey, and other states.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.